Gilead Sciences Inc.’s $11 billion bet on Kite Pharma Inc. is poised to pay off, with the approval Wednesday of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.

Topics:  gilead sciences   kite pharma   kite s   cell-therapy   
BING NEWS:
  • Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, Again
    Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury. And Gilead stock jumped in late trades Thursday.
    04/25/2024 - 9:45 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News